In SmithKline Beecham v Generics (UK) Ltd (Jacob J Patents Court; October 23 2001), the Court injuncted Generics (UK) Ltd until trial (now fixed for March 2002) from launching its paroxetine pharmaceutical in the UK. Paroxetine is an active ingredient in some pharmaceuticals for treating depression. SmithKline Beecham's UK patent 2 297 550 covered only particular forms of paroxetine hydrochloride anyhdrate. Generics denied that its form of paroxetine fell within the patent and attacked validity too, but was nevertheless injuncted, pending trial.